Navigation Links
FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Date:10/14/2011

the level of a liver enzyme that may be indicative of tissue or liver damage at unsafe amounts.

The most serious side effect seen in about two percent of patients treated with Ferriprox was the development of agranulocytosis, a serious and potentially life-threatening reduction in the number of granulocytes (a type of white blood cell that fights infection).

The therapy is being approved under the FDA's accelerated approval program, designed to provide patients with earlier access to promising new drugs followed by further studies to confirm the drug's clinical benefit.

The accelerated approval program allows the agency to approve a drug to treat a serious disease based on clinical data showing that the drug has an effect on an endpoint that is reasonably likely to predict a clinical benefit to patients, or on an effect on a clinical endpoint other than survival or irreversible morbidity (illness).

ApoPharma has agreed to several post-marketing requirement and commitments. One commitment includes further study of the use of Ferriprox in patients with sickle cell disease who have transfusional iron overload.

Earlier this year, the U.S. Department of Health and Human Services (HHS) launched the Sickle Cell Disease (SCD) Initiative bringing together HHS agencies to enhance the quality and quantity of SCD data, develop best practice guidelines and quality of care metrics, improve health care delivery and coordination of care for patients with SCD, facilitate approval of new medical products, and expand research on SCD.  The post-marketing requirement for further study of Ferriprox aligns with the goals of the SCD Initiative.

Ferriprox is marketed by ApoPharma Inc. of Toronto.

For more information:

FDA: Office of Hematology and Oncology Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

FDA: Spotlight o
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014  CVS Caremark Corporation (NYSE: CVS ... August 5, 2014, at 8:30 a.m. (EDT) with analysts ... results. An audio webcast of the conference ... portion of the CVS Caremark website for all interested ... This webcast will be archived and available on the ...
(Date:7/25/2014)...  Acsis Inc., the market leader for supply ... recently posted an article, "Future of Running ... needs for companies, extended supply chain, and explains ... no longer work today.  The article explains how ... mobile technology, machine to machine (M2M) connectivity, and ...
(Date:7/25/2014)... 2014 Research and Markets has ... Devices Market 2014-2018" report to their offering. ... Ophthalmic Diagnostic Device An ophthalmic diagnostic ... defect or deficiency in the human visual pathway. Ophthalmic ... as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... 16 Medicare has been touting the merits of the "competitive" bidding program for durable, or home medical equipment ... facts that exaggerate the benefits and ignore the severe shortcomings of the program. , ... ... , ...
... Pharmaceuticals Inc. (Nasdaq: OSIP ) that it will nominate a full and competing slate of independent directors at OSI Pharmaceuticals, 2010 annual stockholders, meeting. , ... , ... ... ...
Cached Medicine Technology:Discussion of Medicare's 'Competitive' Bidding Program for Home Medical Equipment is Plagued by Myths and Misinformation 2Discussion of Medicare's 'Competitive' Bidding Program for Home Medical Equipment is Plagued by Myths and Misinformation 3Discussion of Medicare's 'Competitive' Bidding Program for Home Medical Equipment is Plagued by Myths and Misinformation 4Discussion of Medicare's 'Competitive' Bidding Program for Home Medical Equipment is Plagued by Myths and Misinformation 5Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals' 2010 Annual Stockholders Meeting 2Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals' 2010 Annual Stockholders Meeting 3Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals' 2010 Annual Stockholders Meeting 4Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals' 2010 Annual Stockholders Meeting 5Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals' 2010 Annual Stockholders Meeting 6Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals' 2010 Annual Stockholders Meeting 7Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals' 2010 Annual Stockholders Meeting 8Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals' 2010 Annual Stockholders Meeting 9Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals' 2010 Annual Stockholders Meeting 10
(Date:7/28/2014)... 2014 Maternal and Family Health Services ... which will be presented at the agency’s 43rd Annual ... at the Westmoreland Club in Wilkes-Barre. , The late ... long-time employee of MFHS. She dedicated her life ... health advocate, and champion for women, children and families ...
(Date:7/28/2014)... study has found that following a healthy lifestyle may ... syndrome. Published early online in CANCER , a ... indicate that children with cancer and adults who had ... how their lifestyle may influence their long-term health. ... to be at increased risk for the metabolic syndrome, ...
(Date:7/28/2014)... 28, 2014 As health insurers design ... to private exchanges. “Private Exchange Strategies for Insurers: ... from Atlantic Information Services, will provide answers to the ... for the future. , Barbara Gniewek, Jonathan Har-Even and ... experience in the private exchange sector — will provide ...
(Date:7/28/2014)... 28, 2014 Mitul R. Patel, DDS ... at the MGE Management Experts Benefit Dinner May 30, ... joined the Dentists to raise funds for the Improving ... Girls Clubs and Youth Programs across America. The funds ... with books and audio books to directly tackle illiteracy ...
(Date:7/28/2014)... Cuidado Casero , an organization of Medicare certified agencies ... Texas, New Mexico, New Jersey, Virginia, and Puerto Rico, was ... of PAM’s 2014 Gala. , North Texas PAMS is ... Texas chapter was created by a handful of Peruvian physicians ... care for the indigent in Peru. The chapter is developing ...
Breaking Medicine News(10 mins):Health News:MFHS Seeking Nominations for Rose Allan Tucker Award 2Health News:Lifestyle choices may affect the long-term heart health of childhood cancer survivors 2Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2
... traditional medicinal system, the Indian Council of Medical Research (ICMR) ... develop drugs //from medicinal plants or multi-herb formulations that have ... valid for next five years was signed by ICMR Director ... K Gupta., ,As per the MoU, the ICMR will ...
... shortfall of the tissue culture variety of anti-rabies vaccine, ... of the restricted nerve tissue variety vaccine till the ... minister Surjyakanta Mishra told reporters here today that the ... few years ago citing side-effects., ,"However, since the ...
... shown by an increased nighttime BP than with a traditional ... researchers at Uppsala University revealed that a high blood pressure ... heart failure. ,Congestive heart failure (CHF) is ... Once diagnosed as having CHF, patients have a 1 in ...
... demand for traditional Indian medicine, a four-year degree course ... University (JU) for the first time in eastern India//. ... second of its kind in the country after Gujarat, ... Sciences (BIPS) in joint venture with West Bengal Health ...
... women has shown that those who indulged in six or ... 3 percent reduction in risk of type 2 diabetes, vis ... scientists were not able to place their finger on the ... they strongly feel that the presence of antioxidants and minerals ...
... MMR vaccine has been shrouded in controversy. Now, Britain's reputed ... to the raging //debates over this vaccine. ,Infact they have ... threat to young lives by forsaking the triple shots of ... and the media to defuse the entire furore over the ...
Cached Medicine News:Health News:Increased Nighttime BP, a Significant Predictor of Congestive Heart Failure 2
All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Intended for one-time use....
Used to provide bladder drainage by percutaneous placement of a balloon catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used to establish and temporarily maintain suprapubic access during endoscopic procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used for pulling sutures from a vaginal incision into the suprapubic area during bladder suspension surgery. The double needle design permits simultaneous suture placement. Supplied sterile in peel-o...
Medicine Products: